dna cure.jpg

Our clinical-stage Company is focused on developing therapeutic products under the guidance of the Food and Drug Administration (FDA) in the area of active cancer immunotherapy (vaccines). This area of therapeutic cancer vaccines is expected by many oncology specialists to provide the next breakthrough in the treatment of cancer beyond the current approaches of surgery, radiation, chemotherapy and passive immunotherapy (monoclonal antibodies).

 

Watch Video

At present, XEME Biopharma is focused on two integrated technology platforms: Aggregon® and Oncolipin. The Aggregon® technology is used by the company in the manufacture of Oncoquest™-CLL and Oncoquest™-L, two innovative lead products of personalized (autologous) cancer vaccines for the treatment of leukemia and lymphoma, respectively.

XEME Investor Information

Read More